A citation-based method for searching scientific literature

Jessica A Baker, Anthony N Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J Marquart, Timothy R Holzer, Leslie O'Neill Reising, Joel D Cook, Sameera R Wijayawardana, Juraj Bodo, Eric D Hsi, Andrew E Schade, Gerard J Oakley. Arch Pathol Lab Med 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients.
Kai Zhang, Huajun Chen, Ye Wang, Lin Yang, Chengzhi Zhou, Weiqiang Yin, Guangsuo Wang, Xinru Mao, Jianxing Xiang, Bing Li,[...]. Oncol Res 2019
20
100

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
86
100

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
38
100

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Huijuan Wang, Ziqi Wang, Guowei Zhang, Mina Zhang, Xiaojuan Zhang, Haixia Li, Xuanxuan Zheng, Zhiyong Ma. Cancer Med 2020
21
100

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
913
100

A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Soo-Ryum Yang, Umut Aypar, Ezra Y Rosen, Douglas A Mata, Ryma Benayed, Kerry Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Drilon,[...]. Clin Cancer Res 2021
18
100



TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
Wen-Xian Wang, Chun-Wei Xu, Yan-Ping Chen, Wei Liu, Li-Hua Zhong, Fang-Fang Chen, Wu Zhuang, Yun-Jian Huang, Zhang-Zhou Huang, Rong-Rong Chen,[...]. J Thorac Dis 2018
23
100

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
288
100

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Claudia Casanova, Nicoletta De Luigi, Marita Mariotti,[...]. Clin Cancer Res 2017
158
100

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
34
100

Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Tatsuji Mizukami, Kouya Shiraishi, Yoko Shimada, Hideaki Ogiwara, Koji Tsuta, Hitoshi Ichikawa, Hiromi Sakamoto, Mamoru Kato, Tatsuhiro Shibata, Takashi Nakano,[...]. J Thorac Oncol 2014
42
100

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, Yoshihiro Hattori, Kadoaki Ohashi, Masahiro Morise, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Makoto Nishio,[...]. Transl Lung Cancer Res 2021
7
100

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.
Diana Bradford, Erin Larkins, Sirisha L Mushti, Lisa Rodriguez, Amy M Skinner, Whitney S Helms, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Jiang Liu,[...]. Clin Cancer Res 2021
33
100

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
Ali G Saad, Beow Y Yeap, Frederik B J M Thunnissen, Geraldine S Pinkus, Jack L Pinkus, Massimo Loda, David J Sugarbaker, Bruce E Johnson, Lucian R Chirieac. Cancer 2008
48
100

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
101
100


State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
90
100

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
52
100

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin, Robin Guo, Stephanie L Wu, Joshua Sabari, Josiah D Land, Ai Ni, Joseph Montecalvo, Darragh F Halpenny, Larry W Buie, Terry Pak,[...]. JCO Precis Oncol 2019
59
100

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
100

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Catherine Labbé, Michael Cabanero, Grzegorz J Korpanty, Pascale Tomasini, Mark K Doherty, Céline Mascaux, Kevin Jao, Bethany Pitcher, Rick Wang, Melania Pintilie,[...]. Lung Cancer 2017
121
100

Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Ying-Hsia Chu, Lori J Wirth, Alexander A Farahani, Vânia Nosé, William C Faquin, Dora Dias-Santagata, Peter M Sadow. Mod Pathol 2020
33
100

Identification and Validation of Noncanonical RET Fusions in Non-Small-Cell Lung Cancer through DNA and RNA Sequencing.
Chan Xiang, Lianying Guo, Ruiying Zhao, Haohua Teng, Yulu Wang, Liwen Xiong, Yuchen Han. J Mol Diagn 2022
4
100


Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
131
100

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A Drilon, I Bergagnini, L Delasos, J Sabari, K M Woo, A Plodkowski, L Wang, M D Hellmann, P Joubert, C S Sima,[...]. Ann Oncol 2016
68
100

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.
Sachiko Arai, Kenji Kita, Azusa Tanimoto, Shinji Takeuchi, Koji Fukuda, Hiroshi Sato, Seiji Yano. Oncotarget 2017
9
100

When mutants gain new powers: news from the mutant p53 field.
Ran Brosh, Varda Rotter. Nat Rev Cancer 2009
808
100

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy.
Minhye Kim, Ji Min Na, Gyeong-Won Lee, Seung Jun Lee, Jong Duk Kim, Jung Wook Yang. J Pathol Transl Med 2021
2
100

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Chang Lu, Xiao-Rong Dong, Jun Zhao, Xu-Chao Zhang, Hua-Jun Chen, Qing Zhou, Hai-Yan Tu, Xing-Hao Ai, Xiao-Feng Chen, Gai-Li An,[...]. J Hematol Oncol 2020
17
100

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Weihua Li, Lei Guo, Yutao Liu, Lin Dong, Lin Yang, Li Chen, Kaihua Liu, Yang Shao, Jianming Ying. J Thorac Oncol 2021
34
100

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
79
100

Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
Aaron C Tan, Amanda O L Seet, Gillianne G Y Lai, Tse Hui Lim, Alvin S T Lim, Gek San Tan, Angela Takano, David W M Tai, Tira J Y Tan, Justina Y C Lam,[...]. J Thorac Oncol 2020
22
100


Uterine Cervical Sarcoma With a Novel RET-SPECC1L Fusion in an Adult: A Case Which Expands the Homology Between RET-rearranged and NTRK-rearranged Tumors.
Paul S Weisman, Morgan Altinok, Erica V Carballo, David M Kushner, Jessica J F Kram, Marc Ladanyi, Sarah Chiang, Darya Buehler, Elizabeth L Dickson Michelson. Am J Surg Pathol 2020
11
100

Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Wenbin Li, Zhihui Zhang, Lei Guo, Tian Qiu, Yun Ling, Jian Cao, Huiqin Guo, Huan Zhao, Lin Li, Jianming Ying. Oncotarget 2016
15
100

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
S-H Lee, J-K Lee, M-J Ahn, D-W Kim, J-M Sun, B Keam, T M Kim, D S Heo, J S Ahn, Y-L Choi,[...]. Ann Oncol 2017
141
100

RET tyrosine kinase signaling in development and cancer.
Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
311
100

Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Mi-Sook Lee, Ryong Nam Kim, Hoseok I, Doo-Yi Oh, Ji-Young Song, Ka-Won Noh, Yu-Jin Kim, Jung Wook Yang, Maruja E Lira, Chang Hun Lee,[...]. Oncotarget 2016
21
100

NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
Alena Skálová, Nikola Ptáková, Thalita Santana, Abbas Agaimy, Stephan Ihrler, Emmanuelle Uro-Coste, Lester D R Thompson, Justin A Bishop, Martina Baněčkova, Niels J Rupp,[...]. Am J Surg Pathol 2019
56
100


Human ret proto-oncogene mapped to chromosome 10q11.2.
Y Ishizaka, F Itoh, T Tahira, I Ikeda, T Sugimura, J Tucker, A Fertitta, A V Carrano, M Nagao. Oncogene 1989
175
100

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
211
100


Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
390
100

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
625
100

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
70
100

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Yunjian Pan, Yang Zhang, Yuan Li, Haichuan Hu, Lei Wang, Hang Li, Rui Wang, Ting Ye, Xiaoyang Luo, Yiliang Zhang,[...]. Lung Cancer 2014
152
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.